News
Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...
Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...
9h
Zacks Investment Research on MSNCan Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...
Discover how Nasiol’s 3-step nano coating system boosts solar panel efficiency, reduces cleaning, and extends lifespan.
In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...
Explore more
Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...
Citi analysts wrote in a note to clients that while SAP's revenue forecast has limited potential for another raise, the company could still upgrade its projections for operating profit. Baader ...
Microsoft and Boulder-based company, Atom Computing, are building the world’s most powerful quantum computer in Denmark.
1d
Zacks Investment Research on MSNNovo Nordisk (NVO) Stock Sinks As Market Gains: What You Should KnowIn the latest trading session, Novo Nordisk (NVO) closed at $65.29, marking a -2.61% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.54%. Meanwhile, the Dow ...
An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to pharmaceutical companies Pfizer and Eli Lilly.
The sale represents Clever Culture’s fifth engagement with a leading pharma manufacturer, including AstraZeneca, Bristol Myers Squibb and Thermo Fisher. The company is due to report its Q4 FY25 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results